|
|
Volumn 29, Issue 11, 2006, Pages 2561-
|
|
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Response to Knopp [8]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATORVASTATIN;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PLACEBO;
HEPTANOIC ACID DERIVATIVE;
HYPOCHOLESTEROLEMIC AGENT;
PYRROLE DERIVATIVE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
BLOOD PRESSURE REGULATION;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG SAFETY;
FOLLOW UP;
HAZARD RATIO;
HEART INFARCTION PREVENTION;
HUMAN;
ISCHEMIC HEART DISEASE;
LETTER;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OUTCOME ASSESSMENT;
TREATMENT DURATION;
CORONARY ARTERY DISEASE;
NOTE;
ANGINA PECTORIS;
BLOOD PRESSURE MEASUREMENT;
CARDIOVASCULAR RISK;
HEART INFARCTION;
HOSPITALIZATION;
PRIMARY PREVENTION;
SECONDARY PREVENTION;
TREATMENT OUTCOME;
ANTICHOLESTEREMIC AGENTS;
CORONARY DISEASE;
DIABETES MELLITUS, TYPE 2;
HEPTANOIC ACIDS;
HUMANS;
PYRROLES;
|
|
EID: 33845491739
PISSN: 01495992
EISSN: 01495992
Source Type: Journal
DOI: 10.2337/dc06-1487 Document Type: Letter |
|
Times cited : (8)
|
|
References (3)
|
